Cargando…
FRI067 Efficacy And Safety Of Glucagon-like Peptide 1 Analogs And Agonists (aGLP1) In Overweight/Obese Patients: A Systematic Review And An Updated Network Meta-analysis
Disclosure: C.H. Silva: None. E. Mund: None. J. Watanabe: None. V. José: None. Y. Lorene: None. L. Lucena: None. J.G. Lima: None. Background: Obesity is a chronic disease related to mortality worldwide. aGLP1 are the more effective therapeutic class for weight loss. We aimed to evaluate the efficacy...
Autores principales: | Silva, Caroliny Hellen, Mund, Eduardo, Watanabe, Janine, José, Victor, Lorene, Yasmin, Lucena, Larissa, Lima, Josivan G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553987/ http://dx.doi.org/10.1210/jendso/bvad114.077 |
Ejemplares similares
-
FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity
por: Botero Suarez, Carlos S, et al.
Publicado: (2023) -
FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist
por: Fansa, Sima, et al.
Publicado: (2023) -
FRI075 Single Center Retrospective Matched Cohort Study Of glp1ra-induced Weight Loss In Patients With Post-bariatric Weight Regain Vs Non-surgical Controls
por: Carmen Rivadeneira, Ana Del, et al.
Publicado: (2023) -
FRI014 Exploring The Epigenetic Fingerprint Of Sedentary Behavior
por: Brener, Avivit, et al.
Publicado: (2023) -
FRI046 Clinical Phenotyping Of Adults With Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2023)